ASPIRIN: Neurodevelopmental Follow-up Trial

Completed · Has a placebo group

Conditions studied: Neurodevelopmental Abnormality

In brief

A total of 620 children will be enrolled in this study from six sites in sub-Saharan Africa, South Asia, and Latin America. Half of the children's mothers will have taken aspirin and half will have taken placebo. This will allow the researchers to compare results of the two groups of children and determine if children exposed antenatally to low dose aspirin will have scores on the Bayley Scales of Infant Development-III (BSID-III) examination at 36 months of life (+/-3months) that are not inferior to the child's peers who were not exposed (i.e., by no more than a margin of 4 points).

Key facts

Study ID
NCT04888377
Run by
NICHD Global Network for Women's and Children's Health
People needed
666
Starts
2021-09-01
Expected to finish
2022-06-15
Last updated by the study team
2024-10-21

Who can join

Age: 3 and older, up to 3. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.